MDV Medivation

SAN FRANCISCO, Feb. 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that David Hung, M.D., president and chief executive officer, will present at the 9th Annual BIO CEO & Investor Conference on Monday, February 12, at 12:30 p.m. Eastern Time at the Waldorf- Astoria Hotel in New York. Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon(TM) for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer. The Company reported topline results from its Phase 2 efficacy study of Dimebon in Alzheimer's disease in September 2006, demonstrating that Dimebon met all five efficacy endpoints with strong statistical significance compared with placebo. Dimebon-treated patients also showed statistically significant improvement over baseline on all five efficacy endpoints. Results of the trial will be presented for the first time at a scientific meeting at the 8th International Conference on Alzheimer's and Parkinson's Diseases: Progress and New Perspectives in Salzburg, Austria, in March. A live audio webcast of Dr. Hung's presentation will be available on the Company's website at http://www.medivation.com/, and a replay will also be available for 30 days following the live presentation. About Medivation Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs - Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com/. This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2005, and its Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2006, June 30, 2006, and September 30, 2006, include more information about factors that could affect the Company's financial and operating results. DATASOURCE: Medivation, Inc. CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc., +1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners, +1-415-946-1064, for Medivation

Copyright